Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 18th International Conference on Nephrology & Urology Osaka, Japan.

Day 1 :

Nephrology & Urology 2019 International Conference Keynote Speaker Simon Allen photo

Simon Allen obtained his PhD in Medicine in 1978. For many years he was treating patients with chronic internal diseases, including various kidney problems: nephritis,
nephrosis, chronic kidney failure and kidney stones, developing diets for them. Later he headed Health Clinic for the treatment of chronic internal conditions. Then, he
devoted two decades to further medical research and developed Thermobalancing therapy® and Dr. Allen’s devices for chronic internal diseases, which received a patent
in the USA, as “Therapeutic Device and Method”. He is Director of Fine Treatment, United Kingdom, which distributes these devices worldwide.


Thermobalancing therapy® (TT) and Dr. Allen’s therapeutic devices (DATD) provide a side effects free treatment for common
chronic urological diseases, such as benign prostatic hyperplasia (BPH), chronic prostatitis and kidney stone disease. TT and
DATD received US patent as “Therapeutic Device and Method”. TT is based on a new understanding of the origin of diseases that
states that all chronic internal diseases have the same root, the pathological activity of capillaries. As a result of changes in small
blood vessels, the focus of hypothermia becomes a continuous trigger in the affected tissue, which gradually increases the pressure
in the affected organ that leads to its malfunction. Therapeutic device applies a natural thermoelement, which accumulates the
body heat, to the projection of the affected organ eliminating the focus of hypothermia. For prostate problems, thermoelement
must be applied to the coccyx area and to dissolve kidney stones 2 thermoelements must be applied to the projection of kidneys.
Dr. Allen’s device is a class 1 medical device, so it can be used by everyone at home. Two clinical trials on TT confirmed its
effectiveness. After six-month use of DATD in 124 men with BPH, the prostate volume (mL) decreased from 45.1 to 31.8 and
urinary symptoms score from 14.3 to 4.7. In men with chronic prostatitis, after six-month use of DATD pain reduction ranged
from 10.3 to 3.5, and prostate volume (mL) from 31.7 to 27.0. There were no changes in the control groups. Thus, TT is an effective
tool for urological conditions.